ARS Pharmaceuticals, Inc. - Common Stock SPRY 深 沪
等待开盘 12-20 09:30:00 美东时间
10.46
+0.640
+6.52%
华盛通- 最 高11.45
- 今 开9.84
- 成交量 199.15万股
- 最 低 7.97
- 昨 收 9.82
- 总市值 0
- 52周最高 18.89
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 6.66
- 委 比 -48.31%
- 总股本 --
- 历史最高 63.41
- 量 比 1.37
- 振 幅 35.44%
- 历史最低 0.00
- 每 手 1
- 风险率 2.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Earnings Outlook For ARS Pharmaceuticals
ARS Pharmaceuticals (NASDAQ:SPRY) is set to give its latest quarterly earnings ...
11-08 02:04
ARS Pharmaceuticals Launches Get Neffy On Us Commercial Program
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to
11-04 21:04
Analyst Ratings For ARS Pharmaceuticals
In the preceding three months, 4 analysts have released ratings for ARS Pharmac...
2024-09-10 02:00
Cantor Fitzgerald Reiterates Overweight on ARS Pharmaceuticals, Maintains $30 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and maintains $30 price target.
2024-09-10 00:15
ARS Pharmaceuticals Launches Pre-Ordering Services For neffy To Help Patients Access The Treatment For Type I Allergic Reactions, Including Anaphylaxis
Patients can request a prescription from their existing healthcare provider, or meet with a physician virtually, to request a prescription for neffy ahead of product availability expected by late September Visit neffy.com to pre-order and access comprehensive patient assistance programs available ...
2024-09-04 20:19
ARS Pharmaceuticals Says EC Approves EURneffy for Emergency Treatment of Allergic Reactions
10:45 AM EDT, 08/26/2024 (MT Newswires) -- ARS Pharmaceuticals (SPRY) said Monday the European Commission has approved EURneffy for the emergency treatment of allergic reactions including anaphylaxis. The adrenaline nasal spray will serve as the first needle-free treatment for severe allergies in th...
2024-08-26 22:45
ARS Pharmaceuticals' EURneffy Adrenaline Nasal Spray Approved By European Commission For Emergency Treatment Of Severe Allergic Reactions
Marking First New Delivery Method In EU In Over 30 Years
2024-08-26 21:30
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned
Earlier this month, the FDA approved ARS Pharmaceuticals Inc’s (NASDAQ:SPRY) Neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), for adult and pediatric patients. The nasal spray version of epinephrine i...
2024-08-23 23:43
